Therapeutic Asset Ratings

615 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Envafolimab Liver Metastasis	Fudan University	P2	CCC (53)
Epirubicin Hormone Receptor Negative Tumor	Fudan University	P2	CCC (53)
Epirubicin Hormone Receptor Positive Tumor	Fudan University	P2	CCC (53)
ERIBULIN MONOMETHANESULFONATE Hormone Receptor Positive Tumor	Fudan University	P2	CCC (53)
ETOPOSIDE HR+HER2- Breast Cancer	Fudan University	P2	CCC (53)
ETOPOSIDE Perioperative Immunotherapy	Fudan University	P2	CCC (53)
Famitinib Hormone Receptor Negative Tumor	Fudan University	P2	CCC (53)
Famitinib Hormone Receptor Positive Tumor	Fudan University	P2	CCC (53)
FLUOROURACILUM ctDNA	Fudan University	P2	CCC (53)
Fluzoparib Breast Neoplasm	Fudan University	P2	CCC (53)
Fluzoparib Hormone Receptor Negative Tumor	Fudan University	P2	CCC (53)
Fluzoparib Hormone Receptor Positive Tumor	Fudan University	P2	CCC (53)
Fruquintinib Exocrine Pancreatic Carcinoma	Fudan University	P2	CCC (53)
Fruquintinib Ovarian Cancer	Fudan University	P2	CCC (53)
hb1801 Breast Neoplasm	Fudan University	P2	CCC (53)
hb1801 Hormone Receptor Negative Tumor	Fudan University	P2	CCC (53)
hb1801 Hormone Receptor Positive Tumor	Fudan University	P2	CCC (53)
hb1801 Triple-Negative Breast Carcinoma	Fudan University	P2	CCC (53)
Hrs-1167 Breast Carcinoma	Fudan University	P2	CCC (53)
Hrs-2189 Metastatic Prostate Carcinoma	Fudan University	P2	CCC (53)
Hrs-4508 Breast Neoplasm	Fudan University	P2	CCC (53)
Hrs-4508 Hormone Receptor Negative Tumor	Fudan University	P2	CCC (53)
Hrs-4508 Hormone Receptor Positive Tumor	Fudan University	P2	CCC (53)
Hrs-4508 Triple-Negative Breast Carcinoma	Fudan University	P2	CCC (53)
Hrs-4642 Colorectal Cancer	Fudan University	P2	CCC (53)

Showing 251 to 275 of 615 assets

PreviousPage 11 of 25Next